[1]徐风燕 孙飞龙.非瓣膜性心房颤动患者华法林抗凝质量的临床研究[J].心血管病学进展,2020,(8):868-872.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.021]
 XU Fengyan,SUN Longfei.(Department of Cardiology,Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University,Urumqi 831100,Xinjiang,China)[J].Advances in Cardiovascular Diseases,2020,(8):868-872.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.021]
点击复制

非瓣膜性心房颤动患者华法林抗凝质量的临床研究()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年8期
页码:
868-872
栏目:
论著
出版日期:
2020-08-25

文章信息/Info

Title:
(Department of Cardiology,Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University,Urumqi 831100,Xinjiang,China)
作者:
徐风燕 孙飞龙
(新疆医科大学附属中医医院心血管内科新疆 乌鲁木齐 831100)
Author(s):
XU FengyanSUN Longfei
(Department of Cardiology,Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University,Urumqi 831100,Xinjiang,China)
关键词:
心房颤动华法林危险因素抗凝质量治疗范围内时间百分比
Keywords:
Atrial fibrillation Warfarin Risk factors Anticoagulation quality Time in therapeutic range
DOI:
10.16806/j.cnki.issn.1004-3934.2020.08.021
摘要:
目的 分析心房颤动(房颤)患者服用华法林抗凝治疗情况及影响抗凝质量的因素。方法 选择2017年8月2019年8月于新疆医科大学附属中医医院定期检测国际标准化比值(INR)的房颤患者纳入研究,最终纳入197例患者。统计INR检测情况,计算抗凝治疗范围内时间百分比(TTR)。TTR65%的患者纳入高质量抗凝组,TTR65%的患者纳入非高质量抗凝组。分别采取单因素分析和二元logistic回归分析方法,分析华法林高抗凝质量的危险因素。结果 患者平均TTR为(31.74±11.02)%,其中高抗凝质量(TTR65%)患者24例(12.18%),45%≤TTR<65%患者35例(17.77%),25%≤TTR<45%患者51例(25.89%),TTR<25%患者87例(44.16%)。采用χ2检验分析影响抗凝质量的相关因素时发现,高质量抗凝组与非高质量抗凝组的年龄、合并症数量2个和脑卒中史比较存在显著性差异(P0.05),其他因素分析未发现显著性差异(P0.05)。Logistic分析得到脑卒中史(OR 4.878)、年龄60岁(OR 3.398)及合并症数量2个(OR 3.160)是患者高抗凝质量的危险因素(P0.05)。结论 房颤患者华法林抗凝质量较差,医护人员需对脑卒中史和年龄60岁房颤患者重点关注、保持合理INR检测频率、及时调整服药剂量,提高患者抗凝质量。
Abstract:
Objective To analyze anticoagulation therapy of warfarin in atrial fibrillation(AF)?patients and influencing factors of anticoagulation quality.Methods A total number of 197 AF patients with international normalized ratio(INR) regular detection in our hospital from August 2017 to August 2019 were collected as a research object.The detection of INR was counted,and the time in therapeutic range (TTR) was calculated.Patients with TTR≥65% were included in high-quality anticoagulation group,and the patients with TTR<65% were included in non-high-quality anticoagulation group.Single factor analysis and binary logistic regression analysis were used to analyze risk factors of high-quality anticoagulation associated with oral warfarin.Results The mean TTR of patients was (31.74±11.02)%.24 cases(12.18%) enjoyed high-quality anticoagulation(TTR≥65%),and the remaining patients included 35 cases with 45%≤TTR<65%, 51 cases with 25%≤TTR<45% and 87 cases with TTR<25%The chi square test was used to analyze the relevant factors affecting the anticoagulation quality,which found significant differences in age,number of complications>2 and stroke history between high-quality anticoagulation group and non-high-quality anticoagulation group(P<0.05),and no significant difference was found in other factors analysis(P>0.05).Logistic regression analysis showed stroke history (OR 4.878),age≤60 years (OR 3.398) and number of complications>2(OR 3.160) were the risk factors of high-quality anticoagulation (P<0.05).Conclusion The patients with AF had poor anticoagulation quality of warfarin.The medical staff should pay more attention to the patients with stroke?history and age≤60 years,keep reasonable INR detection frequency,adjust dosage in time,in order to improve the anticoagulation quality of patients.

参考文献/References:

[1].Zhou YMa J,Zhu W,et al.Efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation across BMI categories:a systematic review and meta-analysis[J].Am J Cardiovasc Drug,2019,20(1):51-60.
[2].Goriacko P,Veltri KT.Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation[J].Eur J Haematol,2018,100(5):488-493.
[3].Yoshida Y,Watarai M,Fujii K.Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation:results of the Japanese subgroup of the RE-CIRCUIT trial[J].J Arrhythm,2018,34(2):148-157.
[4].Pratt NL,Ramsay E,Ellett LMK,et al.Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin:a sequential cohort study[J].BMJ Open,2019,9(5):e026486.
[5].陈文文党和勤耿涛等影响房颤患者华法林抗凝控制质量的因素分析[J]中国医院药学杂志2016,36(24):2191-2194.
[6].Inoue H,?Atarashi H,?Kodani E,et al.Regional differences in frequency of warfarin therapy and thromboembolism in Japanese patients with non-valvular atrial fibrillation—Analysis of the J-RHYTHM Registry[J].Circ J,2016,80(7):1548-1555.
[7].Makar-Au?perger K,Kr?elj K,Lovri? Ben?i? M,et al.Warfarin dosing according to the genotype-guided algorithm is most beneficial in patients with atrial fibrillation:a randomized parallel group trial[J].Ther Drug Monit,2018,40(3):362-368.
[8].黄从新张澍黄德嘉等代表中华医学会心电生理和起搏分会、中国医师协会心律学专业委员会心房颤动防治专家工作委员会心房颤动目前的认识和治疗建议-2015[J]中国心脏起搏与心电生理杂志2015,29(5):377-434.
[9].苏轮薛俊仙胡超等436例老年心房颤动病人的临床特点分析[J]中西医结合心脑血管病杂志2017,15(20):2616-2618.
[10].Rosendaal FR,Cannegieter SC,van der Meer FJ,et al.A method to determine the optimal intensity of oral anticoagulant therapy[J].Thromb Haemost,1993,69(3):236-239.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
 HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(8):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
 DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(8):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
 ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
 ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]王鹏举,综述,陈茂,等.华法林相关性肾病[J].心血管病学进展,2016,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.018]
 WANG Pengju,CHEN Mao.Warfarin-related Ephropathy[J].Advances in Cardiovascular Diseases,2016,(8):167.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.018]
[6]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
 HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[7]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
 WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[8]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
 XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[9]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
 ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(8):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[10]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
 WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(8):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]

备注/Memo

备注/Memo:
基金项目:新疆医科大学附属中医医院课题(ZYY201701)
收稿日期:2020-03-16
更新日期/Last Update: 2020-11-02